Scandinavian Biopharma

We are developing the first vaccine for protection against diarrhoea caused by ETEC in travellers, military, health care personnel and endemic populations with a key focus on the most vulnerable – children under five years of age in Low- and Middle-Income Countries.

What we do

We are a research-based specialty biopharma company determined to give people worldwide a longer and better life.

We are developing the first vaccine for protection against diarrhoea caused by ETEC in both travellers and endemic populations.

We distribute a wide range of specialty biopharma products with focus on vaccines and immunoglobulins.

Our organisation

Scandinavian Biopharma has all the key competences for a successful vaccine development and distribution business. The management has been responsible for the development, manufacturing, registration and global launch of new vaccines, as well as running significant global operations within several biotech and big pharma companies.

Our Research & Development

Our Research & Development activities are mainly focused on the development of the first vaccine in the world protecting against diarrhoea caused by ETEC in collaboration with University of Gothenburg. A proof that we are on the right track is that we have received significant funding supporting our vaccine development from Horizon 2020 (EU), EDCTP (EU) and PATH, an important product development partner of the Bill and Melinda Gates Foundation.

Our Distribution business

Scandinavian Biopharma represents all key competences for a successful distribution business including registration of new products. Scandinavian Biopharma has a senior commercial team with more than 20 years of experience from biotech, big pharma and the medtech industry. In 2018 sales coming from the distribution business reached 81,3 million SEK (8 million Euro) with an organic growth of 58% over 2017. The Scandinavian Biopharma group is profitable since 2013.